Novo Nordisk - 42 Year Stock Price History | NVO

Historical daily share price chart and data for Novo Nordisk since 1982 adjusted for splits and dividends. The latest closing stock price for Novo Nordisk as of December 09, 2024 is 111.08.
  • The all-time high Novo Nordisk stock closing price was 146.35 on June 25, 2024.
  • The Novo Nordisk 52-week high stock price is 148.15, which is 33.4% above the current share price.
  • The Novo Nordisk 52-week low stock price is 96.53, which is 13.1% below the current share price.
  • The average Novo Nordisk stock price for the last 52 weeks is 123.83.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Novo Nordisk Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2024 124.3587 100.9945 146.3538 99.8100 111.0800 8.56%
2023 83.6861 66.8923 104.2980 64.6359 102.3198 54.79%
2022 53.2088 52.3473 66.1011 44.7976 66.1011 22.65%
2021 42.4509 33.7295 56.3363 31.6659 53.8919 63.39%
2020 30.3831 26.9704 34.8486 22.8574 32.9834 23.31%
2019 23.5199 21.4370 26.9242 21.2400 26.7486 26.73%
2018 21.8944 24.1724 25.9487 19.0317 21.1071 -11.88%
2017 18.9400 15.5513 23.9805 14.2785 23.9537 54.29%
2016 20.8012 24.1443 24.6579 13.6680 15.5254 -36.56%
2015 22.5430 17.6367 25.3789 17.3918 24.4729 39.32%
2014 18.3526 14.9596 20.3514 14.9596 17.5662 16.69%
2013 13.8617 13.2533 15.5240 12.2661 15.0533 15.44%
2012 11.7244 9.1829 13.5913 9.0651 13.0400 44.10%
2011 9.0516 8.6029 10.3190 7.4258 9.0494 3.90%
2010 6.6382 4.9891 8.7097 4.8910 8.7097 79.47%
2009 4.2618 3.9266 5.2695 3.1900 4.8530 27.03%
2008 4.4639 4.6826 5.4290 3.2724 3.8203 -19.75%
2007 3.8951 3.0190 4.9945 2.9753 4.7604 57.36%
2006 2.4254 2.0252 3.0512 1.9537 3.0252 51.05%
2005 1.8885 1.8586 2.1309 1.7259 2.0028 5.26%
2004 1.7219 1.4232 1.9291 1.3524 1.9028 34.62%
2003 1.2004 0.9989 1.4135 0.8613 1.4135 43.96%
2002 1.0748 1.3494 1.3794 0.7580 0.9819 -27.23%
2001 1.3540 1.1877 1.5557 1.1677 1.3494 14.18%
2000 1.1468 0.8921 1.5037 0.8217 1.1818 37.84%
1999 0.7685 0.9193 0.9193 0.6356 0.8574 -2.00%
1998 0.9215 0.9338 1.1134 0.7121 0.8749 -7.45%
1997 0.7025 0.5870 0.9469 0.5739 0.9453 55.02%
1996 0.4820 0.4540 0.6179 0.4134 0.6098 37.25%
1995 0.3599 0.3010 0.4443 0.2913 0.4443 45.29%
1994 0.3209 0.3171 0.3540 0.2832 0.3058 -3.56%
1993 0.2854 0.2809 0.3171 0.2498 0.3171 12.25%
1992 0.2801 0.2870 0.3064 0.2530 0.2825 -0.18%
1991 0.2217 0.1953 0.2925 0.1788 0.2830 44.61%
1990 0.1614 0.1543 0.2012 0.1384 0.1957 25.93%
1989 0.1365 0.1189 0.1612 0.1189 0.1554 30.70%
1988 0.0993 0.0697 0.1281 0.0697 0.1189 84.63%
1987 0.1007 0.0987 0.1248 0.0606 0.0644 -34.29%
1986 0.0916 0.0855 0.1025 0.0785 0.0980 13.16%
1985 0.0830 0.0701 0.1025 0.0682 0.0866 23.54%
1984 0.1234 0.1670 0.1803 0.0634 0.0701 -57.57%
1983 0.1726 0.1250 0.2146 0.1250 0.1652 27.67%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $498.475B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $762.851B 79.01
Johnson & Johnson (JNJ) United States $360.180B 14.61
AbbVie (ABBV) United States $312.024B 16.42
Merck (MRK) United States $262.551B 17.44
AstraZeneca (AZN) United Kingdom $212.640B 18.09
Novartis AG (NVS) Switzerland $207.834B 13.81
Pfizer (PFE) United States $147.908B 10.12
Sanofi (SNY) $122.907B 11.13
Innoviva (INVA) United States $1.200B 9.98